The landscape of sexually transmitted infections (STIs) in the United States remains a significant public health concern, with over 2.4 million cases reported in 2023. However, recent data from the Centers for Disease Control and Prevention (CDC) offer a cautiously optimistic sign: the STI epidemic may be slowing, with declines observed in some key infections. This shift comes after decades of increasing rates, prompting health officials to express a glimmer of hope although emphasizing the need for continued vigilance and investment in prevention efforts.
For years, the U.S. Has grappled with rising STI rates, fueled by factors like decreased access to healthcare, social and economic inequities and changes in sexual behavior. The COVID-19 pandemic further exacerbated the situation, disrupting public health services and diverting resources. Now, the latest CDC data suggest a potential turning point, though the situation remains complex and disparities persist. Understanding these trends is crucial for tailoring effective public health interventions and protecting vulnerable populations.
The CDC’s latest surveillance report reveals a notable decrease in gonorrhea cases for the second consecutive year, falling 7% from 2022 levels and returning to numbers seen before the COVID-19 pandemic in 2019. Perhaps even more encouraging is the trend in syphilis, where overall cases increased by only 1% – a significant deceleration compared to the double-digit increases observed in previous years. Specifically, primary and secondary syphilis, the most infectious stages of the disease, experienced a 10% decline, marking the first substantial decrease in over two decades. This decline was particularly pronounced among gay and bisexual men, with cases dropping 13% – the first decrease in this population since the CDC began tracking these trends in the mid-2000s.
A Slowing, But Not Reversed, Trend
While the declines in gonorrhea and primary/secondary syphilis are encouraging, it’s important to note that STI rates remain high overall. The CDC data also indicate that increases in congenital syphilis – syphilis passed from a mother to her newborn – are slowing, but still represent a serious concern. Nationally, congenital syphilis cases increased by 3% in 2023, a marked decrease from the 30% annual increases seen in prior years, but still representing a substantial public health challenge. The CDC has been actively working to address this issue, recognizing the devastating consequences for affected infants, and families.

.
“I witness a glimmer of hope amidst millions of STIs,” said Jonathan Mermin, M.D., M.P.H., Director of CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention. “After nearly two decades of STI increases, the tide is turning. We must make the most of this moment—let’s further this momentum with creative innovation and further investment in STI prevention.” This sentiment underscores the need to capitalize on these positive trends and strengthen prevention efforts.
Addressing Health Inequities
The STI epidemic does not affect all communities equally. Significant disparities persist, with American Indian/Alaska Native, Black/African American, and Hispanic/Latino individuals, as well as gay and bisexual men, disproportionately impacted. These inequities are rooted in deeply entrenched social and economic factors, including poverty, lack of health insurance, limited access to healthcare, and stigma. Addressing these systemic barriers is essential for achieving equitable STI prevention and control.
The CDC recognizes the importance of addressing these disparities and has launched several initiatives to promote health equity. These efforts include expanding access to STI testing and treatment in underserved communities, providing culturally tailored prevention messages, and training healthcare providers to address the unique needs of diverse populations. The Department of Health and Human Services (HHS) has also launched initiatives to combat the syphilis surge, recognizing the urgent need for a coordinated response. One year into these efforts, HHS reports progress in several key areas.
New Tools and Strategies in STI Prevention
Alongside the encouraging data, several recent developments offer new hope in the fight against STIs. The CDC has issued guidelines for doxycycline post-exposure prophylaxis (doxy PEP), a strategy to prevent bacterial STIs like chlamydia, gonorrhea, and syphilis after potential exposure. Doxy PEP is currently recommended for certain populations, and research is ongoing to determine its potential benefits for a wider range of individuals.
the Food and Drug Administration (FDA) has recently authorized at-home tests for syphilis, gonorrhea, and chlamydia, increasing access to convenient and confidential testing options. The FDA’s authorization of a syphilis self-test in November 2023 represents a significant step forward in expanding access to early detection and treatment. Similarly, the FDA authorized the first at-home test for chlamydia and gonorrhea in December 2023. These self-tests empower individuals to grab control of their sexual health and seek timely care if needed.
A nationally coordinated response to the U.S. Syphilis epidemic is being spearheaded by the National Syphilis and Congenital Syphilis Syndemic Task Force, bringing together federal agencies, state and local health departments, and community organizations to address this critical public health issue.
Key Takeaways
- STI rates remain high in the U.S., but recent data suggest a potential slowing of the epidemic.
- Declines have been observed in gonorrhea and primary/secondary syphilis cases, particularly among gay and bisexual men.
- Congenital syphilis cases are still increasing, but at a slower rate than in previous years.
- Significant health inequities persist, with certain populations disproportionately affected by STIs.
- New tools and strategies, such as doxycycline PEP and at-home tests, are expanding prevention and testing options.
However, sustained progress requires a multifaceted approach. Prioritizing the STI epidemic at all levels of government, investing in robust public health systems and a well-trained workforce, and expanding access to testing and treatment are crucial steps. Delivering STI services in accessible outreach settings, such as emergency departments, and addressing the social determinants of health that contribute to disparities are also essential. The CDC estimates that a robust public health workforce is critical, with significant funding needed to support these efforts.
The fight against STIs is far from over, but the recent data offer a glimmer of hope. By building on these positive trends, investing in innovative prevention strategies, and addressing the underlying social and economic factors that drive disparities, People can function towards a future where STIs are no longer a major public health threat. The next major update on STI trends is expected from the CDC in late 2024, providing further insights into the evolving epidemic and the effectiveness of ongoing prevention efforts.
What are your thoughts on the recent STI data? Share your comments below, and please share this article with your network to raise awareness about this important public health issue.